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Abstract
Background
The RET S836S variant has been associated with early onset and increased risk for meta-
static disease in medullary thyroid carcinoma (MTC). However, the mechanism by which
this variant modulates MTC pathogenesis is still open to discuss. Of interest, strong linkage
disequilibrium (LD) between RET S836S and 3'UTR variants has been reported in Hirsch-
sprung's disease patients.
Objective
To evaluate the frequency of the RET 3’UTR variants (rs76759170 and rs3026785) in MTC
patients and to determine whether these variants are in LD with S836S polymorphism.
Methods
Our sample comprised 152 patients with sporadic MTC. The RET S836S and 3’UTR
(rs76759170 and rs3026785) variants were genotyped using Custom TaqMan Genotyping
Assays. Haplotypes were inferred using the phase 2.1 program. RETmRNA structure was
assessed by Vienna Package.
Results
The mean age of MTC diagnosis was 48.5±15.5 years and 57.9% were women. The minor
allele frequencies of RET polymorphisms were as follows: S836S, 5.6%; rs76759170,
5.6%; rs3026785, 6.2%. We observed a strong LD among S836S and 3’UTR variants
(|D’| = -1, r2 = 1 and |D’| = -1, r2 = 0,967). Patients harboring the S836S/3’UTR variants pre-
sented a higher percentage of lymph node and distant metastasis (P = 0.013 and P<0.001,
respectively). Accordingly, RNA folding analyses demonstrated different RNA secondary
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structure predictions for WT(TCCGT), S836S(TTCGT) or 3’UTR(GTCAC) haplotypes. The
S836S/3’UTR haplotype presented a greater number of double helices sections and lower
levels of minimal free energy when compared to the wild-type haplotype, suggesting that
these variants provides the most thermodynamically stable mRNA structure, which may
have functional consequences on the rate of mRNA degradation.
Conclusion
The RET S836S polymorphism is in LD with 3’UTR variants. In silico analysis indicate that
the 3’UTR variants may affect the secondary structure of RET mRNA, suggesting that these
variants might play a role in posttranscriptional control of the RET transcripts.
Introduction
Medullary thyroid carcinoma (MTC), a malignant tumor originating in parafollicular C cells of
the thyroid, represents about 4% of all thyroid cancers [1]. MTC is mainly sporadic (75%), but
may also be part of an inherited disorder transmitted as an autosomal dominant trait with
100% penetrance, referred to as multiple endocrine neoplasia type 2 (MEN 2). The MEN 2 syn-
drome is classified into three distinct clinical subtypes: MEN type 2A (MEN 2A), characterized
by the presence of MTC, pheochromocytoma (PHEO), and hyperparathyroidism (HPT); MEN
type 2B (MEN 2B), that includes MTC, PHEO, ganglioneuromatosis, and marfanoid habitus;
familial MTC (FMTC), characterized by MTC as the only feature of the disease [2,3].
The RET (REarranged during Transfection) proto-oncogene is the susceptibility gene for
hereditary MTC and RETmolecular analysis is now considered critical in MTC management
[4,5]. Genotype–phenotype correlation has been reported and mutations in exons 5, 8, 10, 11,
14, 15 or 16 occur in more than 98% of MEN2 families [4,5]. The RET gene, a member of the
cadherin superfamily, encodes a receptor tyrosine kinases, which are cell-surface molecules
that transduce signals for cell growth and differentiation. This gene plays a crucial role in neu-
ral crest development, and it can undergo oncogenic activation in vivo and in vitro by cyto-
genetic rearrangement. Alternative splicing of the RET gene results in the production of
RET51, RET43 and RET9 isoforms, contain 51, 43 and 9 amino acids in their C-terminal tail,
respectively. The biological roles of isoforms RET51 and RET9 are the most well studied
in-vivo as these are the most abundant isoforms in which RET occurs [6]. RET9 and RET51
isoforms appear to be coexpressed in MTC [7,8]. The RET 51 isoform with MEN2-related
mutations might activate the Ras signaling cascade with a greater efficiency than the RET 9 iso-
form. Nevertheless, it has not been observed significant differences in the transforming ability
of RET51 and RET9 [6].
Although much is known about hereditary MTC, the molecular mechanisms underlying
sporadic MTC tumors remain to be clarified. Somatic RET point mutations in exon 16
(M918T) and gene deletions are described in 23–66% of sporadic MTC [9–11]. However, these
mutations are not uniform among the various cell subpopulations, suggesting that the tumor
may be of polyclonal origin or that the RET mutations are not the initial events in MTC tumor-
igenesis. Thus, in the last years, several studies have also investigated the relationship between
the presence of single nucleotide polymorphisms (SNPs) in the RET gene and susceptibility or
progression of sporadic MTC. The RET neutral variants L769L, S836S, and S904S have been
associated with clinical presentation and disease outcome in sporadic MTC patients [12]. Par-
ticularly, the S836S variant (codon 836 of exon 14, SerAGC/SerAGT) has been found over-rep-
resented in sporadic MTC patients from Germany, Spain, and the United States [13,14]. This
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variant also has been associated with two-to-three-fold increase in the risk of MTC in the Span-
ish population [14], early onset of MTC and increased risk for metastatic disease [15]. These
results are in agreement with a recent meta-analysis that demonstrated an association between
sporadic MTC susceptibility and S836S polymorphism [16]. Nevertheless, other studies failed
to demonstrate any effect of RET variants on risk of development or on the natural course of
MTC [17–19].
On the other hand, the mechanism by which SNPs modulate the MTC pathogenesis is still
open to discussion [12,16]. One of the proposed mechanisms suggests that the S383S neutral
variant might be in linkage disequilibrium (LD) with an unknown functional variant, which
may modulate the RET oncogene expression by affecting the mRNA stability [13,20,21].
Recently, the presence of multiple RET risk alleles has been associated with increased estimated
risk for MTC development and aggressiveness, indicating that these variants could be acting in
an additive manner on disease pathogenesis [22].
The RETmutations are also associated with Hirschsprung's disease (HSCR), a developmen-
tal disorder of the enteric nervous system, characterized by the absence of ganglion cells in the
distal colon resulting in functional obstruction [23]. However, contrasting with the gain-of
function effect caused by RETmutations in MTC, loss-of-function RETmutations account for
approximately 50% of familial and 7–35% of sporadic HSCR patients [24,25]. A potential
explanation for these distinct effects is that constitutive RET activation is sufficient to induce
neoplastic transformation of the C-cells and adrenal chromaffin cells, but not to produce a tro-
phic response in the precursor neurons [26]. Of interest, RET polymorphisms and haplotypes
have been described as underrepresented in HSCR patients, which could act as low susceptibil-
ity loci and modify the phenotype of HSCR [27–29]. Particularly, the haplotype including the
uncommon S836S polymorphic allele has shown a low penetrant protective effect against the
disease [30,31]. Interestingly, Griseri et al 2007 report a strong LD among S836S and 3’untrans-
lated region (3’UTR) variants (rs76759170, G>A and rs3026785, T>C) [32]. The 3’UTR gene
region is emerging as fundamental and effective in regulating gene expression at posttranscrip-
tional levels (pre-mRNA processing, mRNA stability and translational regulation) [33], sug-
gesting that 3'UTR variants might have a functional effect on the RET expression [32].
Here, we evaluated the presence of linkage disequilibrium between S836S and 3’UTR RET
variants in MTC patients and assessed whether the 3'UTR variants could play a role in RET
expression.
Material and Methods
Ethics Statement
The information obtained during the study did not affect the patients’ diagnosis or treatment.
The protocol was approved by the Committee on Research Ethics from Hospital de Clínicas de
Porto Alegre (project number 12–0225), and all patients and/or their legal representatives pro-
vided written informed consent for the study. Clinical investigation was conducted according
to the principles expressed in the Declaration of Helsinki.
Patients
Patients with a diagnosis of MTC attending the Endocrine Division at Hospital de Clínicas de
Porto Alegre were invited to participate in the study. Since 1997, our division has been a refer-
ence center for RETmutation screening in Brazil, and therefore, patients referred to us by
other Brazilian centers were also invited to participate.
The patients underwent a complete clinical examination, laboratory tests (levels of basal cal-
citonin (Until December 2003, Calcitonin IRMA-DSL7700, Diagnostic Systems Laboratories,
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Inc., Webster, TX, USA, reference range<10 pg/ml and, after January 2004, Immulite 2000,
Diagnostic Products Corporation, Los Angeles, CA, USA; reference value (VR) male<12.0 pg/
ml and female<6.0 pg/ml)), plasma parathyroid hormone (PTH; Immulite 2000 Intact PTH,
Diagnostic Products), urinary fractionated metanephrines (HPLC), and, whenever indicated,
diagnostic imaging investigation (cervical ultrasonography, thorax and abdominal computed
tomography (CT)). Selected patients were submitted to whole-body metaiodobenzylguanidine
scintigraphy to rule out distant metastasis.
In our division, the MTC treatment follows the protocols recommended by the current
guidelines [4,5]. Total thyroidectomy was performed in all patients with varying cervical neck
dissection procedures. The diagnosis of lymph node metastasis was based on histological exam-
ination. Patients with suspicious distant metastasis (i.e. the presence of local metastasis and/or
serum calcitonin>150 pg/ml) underwent imaging exams (cervical, thoracic and abdomen CT
(or liver magnetic resonance imaging), and bone scintigraphy). Patients with undetectable cal-
citonin levels were considered free of disease. Tumor staging was performed according to the
current International Union against Cancer TNM classification[34].
Genotyping Assay
RET variants L769L (rs1800861, codon 769, exon 13, LeuCTT/LeuCTG), S836S (rs1800862;
codon 836, exon 14, SerAGC/SerAGT), S904S (rs1800863, codon 904, exon 15, SerTCC/
SerTCG) and 3’UTR (rs3026785, T>C and rs76759170, G>A) were analyzed in DNA
extracted from peripheral blood leukocytes by standardized procedures. Genotype analysis was
performed using Human Custom TaqMan SNP Genotyping Assays (Applied Biosystems, Fos-
ter City, CA, USA), as described previously by [22,35]. Primer and probe sequences used for
genotyping the RET 3’UTR variants were, rs3026785: 5’-CACGTAAATGCAGAAGTTACTAAG
TATTAAGTATTACT-3’ (forward primer), 5’-AGGAACATGATCTGGTTTAATGACCTTT-3’
(reverse primer), VIC-5’-TCTGTCAGTTATTAAAATT-3’, FAM-5’-TGTCAGTTACTAAA
ATT-3’; rs75759170: 5’-ACACGTAACCTGGCTCTAATTTGG-3’ (forward primer), 5’-CT
GCATTTAGTAAGACTATCATTAAGCATATCTGA-3’ (reverse primer), VIC-5’-CACAGTG
TATCTGAAAAA-3’, FAM-5’-CACAGTGTATTTGAAAAA-3’.
The reactions were conducted in a 96-well plate, in a total 5 ml reaction volume using
2-10ng genomic DNA, TaqMan Genotyping Master Mix 1X (Applied Biosystems), and Cus-
tom TaqMan Genotyping Assay 1X. The plates were then positioned in a real-time PCR ther-
mal cycler (7500 Fast Real PCR System; Applied Biosystems) and heated for 10 min at 95°C,
followed by 45 cycles of 95°C for 15s and 62°C for 1min. Fluorescence data files from each
plate were analyzed using automated allele calling software (SDS 2.1; Applied Biosystems).
Haplotype Construction and Linkage Disequilibrium Analysis
The haplotypes were constructed based on the combination of allelic variants and their fre-
quencies were inferred using the phase 2.1 program, which implements a Bayesian statistical
method [36]. We also used the phase 2.1 program to compare the distributions of different
RET haplotypes between MTC patients through permutation analyses of 1000 random repli-
cates [36]. Among all pairs of biallelic loci, we examined widely used measures of linkage dis-
equilibrium (LD), Lewontin’s D’ jD’j and r2 [37].
Somatic M918T RETMutation Analysis
Forty seven paraffin-embedded MTC samples were available by sequencing. Samples were
sequenced at the Unidade de Análises Moleculares e de Proteínas (Centro de Pesquisa Experi-
mental, HCPA) using ABI 3500 Genetic Analyzer with 50 cm capillaries and POP7 polymer
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(Applied Biosystems). PCR products were labeled with 5.0 pmol of the primer 5’-AGGGATAG
GGCCTGGGCTTC-3’ and 1 μL of BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) in a final volume of 10 μL. Labeling reactions were performed in a Veriti1
96-Well Thermal Cycler (Applied Biosystems) with an initial denaturing step of 96°C for 1
min followed by 35 cycles of 96°C for 15 sec, 50°C for 15 sec and 60°C for 4 min. Labeled sam-
ples were purified using BigDye XTerminator Purification Kit (Applied Biosystems) and elec-
troinjected in the automatic sequencer.
Thermodynamic Simulations Methodology
The bioinformatics analyses were realized based on haplotypes inferred by Phase program.
Additionally, we also used the haplotype carrying only the S836S variant (TTCGT). No patient
harbored only S836S polymorphism was observed in our study population, this variant occurs
only in combination with L769L and 3’UTR variants (GTCAC haplotype).
The preliminary analysis was realized in both, wild type (TCCGT_WT haplotype) and poly-
morphic sequences (GCCGT, TCGGT and GTCAC haplotypes), with the RNAfold algorithm
provided by the Vienna Package 2.1.5. This algorithm provides the optimal RNA secondary
structure and its associated minimal free energy (MFE) for each input sequence [38].
The Vienna Package [38] program RNAsubopt with default parameters was used to gener-
ate suboptimal secondary structures of all haplotypes. Since the number of possible suboptimal
structures for each sequence is exceedingly large we randomly selected a subset of those using
the -p option. In this analysis we used subsets of 2900 structures for each sequence. The result-
ing dot-bracket files were evaluated as follows: 1) by counting the number of continuous base-
pairs in double helices of at least 6 bp (number of double helices sections—NDH); 2) by calculat-
ing the resulting Gibbs free energy (kcal/mol) with RNAeval from the Vienna Package [38].
First we performed these calculations for the wild type sequence and obtained average num-
bers of base-pairs, total melting index and Gibbs free energies. Then we compared each subop-
timal structure of the polymorphic haplotype to those averages and counted how many times
they present higher thermodynamic stability (lower Gibbis free energy). This gives us a mea-
sure that represents the probability which polymorphic haplotype may result into a more stable
structure than the wild-type sequence.
The NCBI Reference Sequence accession number for the RET gene was NM_020975.4
(mRNA).
Immunohistochemistry Analysis
Immunohistochemistry analysis (IHC) was performed on thin sections (3 μm) of previously
formalin-fixed and paraffin-embedded tissues. The antibody used was monoclonal rabbit anti-
human RET (ab134100; Abcam Inc., Cambridge, MA, USA), Sections representing MTC were
submitted to routine immunohistochemical technique, which comprises deparaffination and
rehydration, antigenic recovery, inactivation of endogenous peroxidase, and blockage of unspe-
cific reactions. Primary antibodies were incubated overnight at a temperature of 4°C, at dilu-
tions of 1:400 followed by application of streptavidin horseradish peroxidase conjugate (LSAB;
DakoCytomation, Via Real Carpinteria, CA, USA), and diaminobenzidine tetrahydrochloride
(Kit DAB; DakoCytomation). Absence of the primary antibody was used as a negative control.
Semi-Quantitative Analysis for the Intensity of Positive Staining in
Tissues
The intensity of positive staining of RET was performed by digital image analysis using the
Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA). Two independent
30UTR RET Polymorphisms in Linkage Disequilibrium with S836S Variant
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researchers (L.C. and J.O.S) carried out blind analysis of the intensity of brownish-colored
immunostaining in pixels in 4 to 12 fields from each slide, according of the tumor size area.
The mean number of pixels identified by both researchers in each sample was used. All of the
images were taken using the same microscope and camera sets [39].
Statistical Analysis
Results are expressed as mean ± S.D. or median (IQ 25–75) unless otherwise specified. Hardy–
Weinberg equilibrium for each polymorphism was assessed by χ2 tests. Baseline characteristics
were compared using χ2 tests or Fisher’s exact test for qualitative variables. Quantitative vari-
ables were compared between groups using Student’s t-test or Mann-Whitney test. The differ-
ences in cumulative lymph node and/or distant metastasis between groups were tested by
Kaplan–Meier curves; comparisons between curves were performed using the log rank test.
The Statistical Package for the Social Sciences 18.0 (SPSS Inc., Chicago, IL, USA) was used, and
P<0.05 was considered as statistically significant.
Results
RET Variants in MTC Patients
The clinical and oncological features of the study subjects are summarized in Table 1. The
median age at diagnosis was 48.5±15.5 years and the percentage of women was 57.9%. The eth-
nic background was 95% Caucasian. The median basal serum calcitonin and CEA levels at
diagnosis were 782 (167–2566) pg/ml and 33.6 (7.13–115.4) ng/ml, respectively. The median
tumor size was 2.3 (1.5–3.35) cm. Seventy-eight patients (58.3%) presented lymph node and
23.1% presented distant metastasis at diagnosis, respectively. The minor allele frequencies
observed were as follows: S836S (5.6%) and 3’UTR RET variants rs76759170 (5.6%) and
rs3026785 (6.2%) (Table 2).
Haplotype Construction and Linkage Disequilibrium Analysis
We used a Bayesian statistical method to estimate the frequency of different haplotypes pro-
duced by the combination of the L769L(rs1800861), S836S(rs1800862), S904S(rs1800863) and
3’UTR(rs3026785 and rs76759170) polymorphisms in MTC patients.
A total of 5 haplotypes were inferred in our study population. The haplotype frequencies
were shown in Table 3. Interestingly, the S836S polymorphism occurs only in combination
with L769L and 3’UTR variants. We observed a strong LD among S836S and 3’UTR variants:
Table 1. The clinical and oncological features of medullary thyroid carcinoma patients.
Total patients (%) 152
Sex female (%) 88 (57.9)
Age at Diagnosis (yr) 1 48.5±15.5
Calcitonin (pg/ml) 2 782 (167–2566)
CEA (ng/ml) 2 33.6 (7.13–115.4)
Tumor Size (cm) 2 2.3 (1.5–3.35)
N1 (%) 77 (58.3)
M1 (%) 27 (23.1)
CEA, carcinoembryonic antigen; N1, lymph node metastasis; M1, distant metastasis.
1Data expressed as mean±S.D.
2Data expressed as median (IQ 25–75).
doi:10.1371/journal.pone.0147840.t001
30UTR RET Polymorphisms in Linkage Disequilibrium with S836S Variant
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S836S and rs76759170 (|D’| = -1, r2 = 1), S836S and rs3026785 (|D’| = -1, r2 = 0.967), and
rs76759170 and rs3026785 (|D’| = -1, r2 = 0.967).
RET Haplotypes and Disease Presentation
Seventeen patients (11.2%) were heterozygous for S836S/3’UTR polymorphic allele (GTCAC
haplotype). Individuals harboring the S836S/3’UTR haplotype (GTCAC) had higher serum cal-
citonin level (1860(1160–7087) vs 579(120–2014) pg/mL, P = 0.014), CEA level (584(145–
4353) vs 26(7–113) ng/mL, P = 0.007) and larger tumor size (3.3(1.8–4.0) vs 2.1(1.4–3.0),
P = 0.062). The S836S/3’UTR RET haplotype (GTCAC) was associated with higher rates of met-
astatic disease as compared to patients without GTCAC haplotype (87.5 vs 53.9%, P = 0.013 and
60 vs 16.8%, P = 0.001) (Table 4). Accordingly, Kaplan–Meier estimates of cumulative lymph
node and distant metastasis yielded distinct curves for patients with or without the S836S/
3’UTR haplotype (P = 0.011 and P<0.001, respectively; Fig 1), further demonstrating that met-
astatic disease occurred earlier in those individuals harboring the S836S/3’UTR variants.
Somatic M918T RETMutation
The somatic RETM918T mutation has been previously associated with lymph node metastases
at diagnosis and could be a confounding factor in our analysis. Thus we also evaluated somatic
RETmutations in our sample population. Forty-seven paraffin-embedded samples were avail-
able. Of them, we failed to extract / amplify DNA from 7 even after several repeated attempts.
Of the 40 DNA samples available for analysis, 13 (32.5%) samples have somatic M918T muta-
tion. There were no significant difference in the frequency of somatic M918T mutation in sam-
ples with or without S836S/3ÚTR variants (10/31 (32.3%) vs. 3/9 (33.3%), P = 1.00; Fisher’s
exact test). In addition, no association was observed between the presence of somatic M918T
mutation with lymph node or distant metastasis (P = 0.614 and P = 0.628, respectively).
Table 2. RETminor allele frequency polymorphisms in medullary thyroid carcinoma patients.
RET Polymorphisms Allele variation Sporadic MTC (n = 152)
S836S (%) C>T 5.6
rs76759170 (%) G>A 5.6
rs3026785 (%) T>C 6.2
doi:10.1371/journal.pone.0147840.t002
Table 3. Haplotypes inferred by the Phase Program.
Presence/absence of HaplotypeFrequency1
Haplotypes L769L S836S S904S rs76759170 rs3026785
TCCGT (WT) 55
GCCGT X 18
TCGGT X 21
GCCGC X X 0.3
GTCAC X X X X 5.6
Haplotype frequencies was calculated by the Phase 2.0 program using permutation test (1000 replications). For simplified representation, the Phase
program shows the haplotypes by the presence of the wild-type or risk alleles.
1 Frequencies calculated by the Phase 2.0 program based on the number of chromosomes.
*The GCCGC haplotype was present in only two patients, thus was not included in our analyzes.
doi:10.1371/journal.pone.0147840.t003
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In Silico Analysis of RET Haplotypes
Our purpose was to evaluate the effect of RET neutral variants on the full RETmRNA structure
(5.6kb). In order to minimize the experimental limitations, increase the accuracy of computer
predictions of RNA secondary structure and perform a more robust analysis, we evaluated the
effect of the RET haplotypes on the optimal and suboptimal mRNA structures. The bioinfor-
matics analyses used all haplotypes inferred by Phase program (Table 3) and included only
synonymous polymorphisms.
As shown in Fig 2, RNA folding analyses have demonstrated different RNA secondary
structure predictions for WT (TCCGT), S836S (TTCGT) and S836S/3’UTR (GTCAC) haplo-
types. We can observe that S836S/3’UTR (GTCAC) haplotype presented a structural modifica-
tion not observed in WT (TCCGT) or S836S (TTCGT) haplotypes.
Table 4. Clinical and oncological features of sporadic medullary thyroid carcinoma patients accord-
ing to the presence of polymorphic haplotype.
Without GTCAC GTCAC P
Total patients (%)* 133 (88.6) 17 (11.3)
Sex female (%) 79 (59.4) 8 (47.1) 0.332
Age at Diagnosis (yr) 48.6±16 45.6±13 0.441a
Calcitonin (pg/ml)1 579 (120–2014) 1860 (1160–7087) 0.014b,d
CEA (ng/ml)2 26 (7–113) 584 (145–4353) 0.007b,d
Size Tumor (cm)3 2.1 (1.4–3.0) 3.3 (1.8–4) 0.062b
N1 (%)4 62 (53.9) 14 (87.5) 0.013c
M1 (%)5 17 (16.8) 9 (60) 0.001c
PHEO, pheochromocytoma; HPT, hyperparathyroidism; N1, lymph node metastasis; M1, distant
metastasis; GTCAC, haplotype harboring L769L, S836S and 3’UTR RET variants; Without GTCAC, all other
haplotype.
* The total of patients available was 150, the two patients carrying the GCCGC were not included in our
analyzes.
1 Data evaluated for 67 patients
2 Data evaluated for 39 patients
3 Data evaluated for 99 patients
4 Data evaluated for 131 patients
5 Data evaluated for 116 patients
aData expressed as mean±S.D.
bData expressed as median (IQ 25–75).
cVariables were compared using the Yates’ X2-test or Fisher’s exact test.
dVariables were compared using the Mann–Whitney U test.
doi:10.1371/journal.pone.0147840.t004
Fig 1. Kaplan–Meier estimates the proportion of sporadic MTC patients with lymph node (A; n = 131;
P = 0.011) or distant metastasis (B; n = 116; P<0.001). The log rank test was used to compare curves.
doi:10.1371/journal.pone.0147840.g001
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Concerning the NDH analyses, the S836S/3’UTR (GTCAC) haplotype presented greater NDH
in both, optimal and suboptimal structures when compared with the WT haplotype (65 vs 64,
Fig 3B and 58 vs 57, Fig 3D, respectively). In agreement, the sequence carrying S836S/3’UTR
(GTCAC) haplotype presented lower levels of MFE when compared to the WT sequence (opti-
mal, -2142.1 vs -2138.6, Fig 3A; suboptimal, -1989.4 vs -1983.1, Fig 3C). Thus, the structure
carrying the 3’UTR variants provides the most thermodynamically stable mRNA secondary
structure when compared to the other.
Immunohistochemistry Analysis
Next, we decided to look whether the presence of the S836S/3’UTR (GTCAC) haplotype was
associated with increased expression of RET protein in paraffin-embedded samples of patients
with or without this haplotype. To minimize confounding factors, we selected only samples
negative for somatic M918T mutation, since studies have demonstrated association between
the presence of this mutation and stronger RET immunostaining [40].
Four samples carrying S836S/3’UTR (GTCAC) and 13 samples without the variants were
available for analysis. Immunostaining for RET were detected in 100% of the samples analyzed.
The overall median of the RET immunoreactivity observed was 220.2 (155–393) pixels. Of
interest, all MTC samples carrying S836S/3’UTR (GTCAC) haplotype uniformly display a very
strong intensity of RET immunostaining (Fig 4A). Remarkably, despite the relative small
Fig 2. The figure shows the optimal mRNA secondary structure of the RET haplotypes. A) Total mRNA
secondary structure of the RETwild-type (WT) haplotype. B) Part of mRNA secondary structure of the RETWT
haplotype. C) Part of mRNA secondary structure of the RET S836S haplotype (TTCGT). D) Part of mRNA
secondary structure of the RET 3’UTR haplotype (GTCAC). Haplotypes generated by RNAfold program
(Vienna Package).
doi:10.1371/journal.pone.0147840.g002
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Fig 3. Theminimal free energy (MFE, kcal/mol) and number of double helices (NDH) were available in
both, optimal and suboptimal structures. For suboptimal structures MFE and NDH are averages over
2900 samples. The variant fragment carrying the S836S and 3’UTR variants (GTCAC haplotype) presented
greaterNDH (B,D) and lower levels of MFE (A,C) when compared to wild-type haplotype (WT, TCCGT), this
fact happens in both, optimal and suboptimal structures. *These analysis included only synonymous
polymorphisms.
doi:10.1371/journal.pone.0147840.g003
Fig 4. Immunostaining of the RET proto-oncogene in GTCAC haplotype carriers & non-carriers. A) Two
representative slices of RET Immunostaining in a sample carrier S836S/3’UTR (GTCAC haplotype) (left) and
non-carrier of this haplotype (right). B) Intensity of RET Immunostaining in samples with or without S836S/
3’UTR (GTCAC haplotype), P = 0.054.
doi:10.1371/journal.pone.0147840.g004
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number of samples, we observed a strong trend towards a significant statistical difference in
the RET immunostaining between samples carrying S836S/3’UTR (GTCAC) haplotype and
those without these variants (392.7 (297–463) vs. 189.5 (152–324), P = 0.054; Fig 4B).
Discussion
In the present study, we have demonstrated that the neutral RET S836S polymorphism is in
linkage disequilibrium with the RET 3’UTR variants (rs3026785 and rs76759170) in patients
with sporadic MTC. Interestingly, the individuals harboring these variants presented more
aggressive disease and metastasis at younger age. Furthermore, the haplotype carrying the
S836S/3’UTR RET variants presented a greater NDH and lower levels of MFE as compared to
the wild-type haplotype, which may have functional consequences on the rate of mRNA degra-
dation. Interestingly, MTC samples carrying S836S/3’UTR (GTCAC) haplotype displayed
stronger RET immunostaining than those without these variants, although the difference did
not reach statistical significance.
Based on the overrepresentation of RET polymorphisms in individuals with MTC, a role for
these genetic variants in the MTC pathogenesis has been suggested. However, the molecular
mechanism by which RET S836S polymorphism affects the development or clinical course of
MTC is still not properly understood. It has been suggested that polymorphisms could influ-
ence the RETmRNA levels. However, quantitative studies in MTC tumor samples show no dif-
ference in RETmRNA levels in patients with or without the S836S polymorphisms [41].
Another hypothesis suggests that bases exchange in the DNAmolecule could create a new
alternative splicing site, leading to the synthesis of a truncated protein, erroneous ligand bind-
ing, microRNA (miRNA) binding, change of structure and mRNA stability as well as a number
of copies [42]. However, the S836S polymorphic variant does not affect DNA–protein binding
or RNA splicing and editing of the RET gene [43]. An alternative way to explain the role of
RET S836S polymorphisms on MTC proposes that this neutral variant can be in LD with an
unknown functional variant [44].
Of interest, a strong LD between S836S polymorphism and 3’UTR variants has been
reported in HSCR disease [32]. The 3’UTR gene region is emerging as fundamental and effec-
tive in regulating gene expression at posttranscriptional levels (pre-mRNA processing, mRNA
stability and translational regulation) [33]. Several sequence elements that may be involved in
mRNA regulation exist in the 30UTR region, including regions rich in adenine and uridine ele-
ments—AU-rich elements (ARE). The ARE mRNAs are regulated by RNA-binding proteins
that can selectively bind to the ARE and promote their mRNA stability or degradation [45].
Elegant studies performed by Griseri et al [31,32] demonstrated that the rs3026785 is located
next to the AUUUA sequence and showed that a single nucleotide substitution may influence
the secondary structure of RETmRNA decreasing RETmRNA degradation in human neuro-
blastoma cells, leading to increases of transcription product and, probably, in the amount of
total RET protein at the cell membrane [31,32].
The S836S polymorphism is associated with increased RET expression in both diseases.
Thus, interestingly, in HSCR, the S836S variant is associated with a protective effect since loss-
of-function RET is causative of the disease [31,32]. We have previously shown that the RET
S836S polymorphism is overrepresented in sporadic MTC patients [22]. Here, we show that
the RET S836S polymorphism is in linkage disequilibrium with RET 3’UTR variants in MTC
patients. Of interest, patients harboring these variants present higher levels of serum calcitonin
and CEA, larger tumor size, and higher rates of metastatic disease as compared to those har-
boring other haplotypes. The somatic RETM918T mutation has been associated with advanced
disease at diagnosis [9,46] and could be a confounding factor in our analysis. However, we
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found no significant difference in the frequency of somatic M918T mutation in samples from
patients with or without S836S/3UTR variants.
To further explore the modulating effect of RET S836S/3’UTR polymorphisms, we thought
to evaluate the effects of the 3’UTR variants on the mRNA structure. Thermodynamics-based
computational methods for prediction of RNA secondary structure are widely used to advance
our understanding of the regulatory roles of cellular RNA [47,48]. These methods use MFE
principles to find the RNA secondary structure from the set of all possible structures for a
given RNA sequence. In this study, in silico analysis showed that the S836S/3’UTR haplotype
(GTCAC) could influence the stability of the RETmRNA. We observed that this haplotype
presents the highest NDH and lower levels of MFE, suggesting that RETmRNA carrying the
S836S/3’UTR haplotype provides the most thermodynamically stable mRNA structure, when
compared to the others. Thus, our data suggest that the S836S/3’UTR haplotype may affect the
secondary structure of RETmRNA, supporting the hypothesis of a functional involvement of
the 3’UTR variant allele in RETmRNA stability. Based on the results presented here, we specu-
lated that S836S variant promotes an increased activity of RET by increasing the mRNA sur-
vival, contributing for gain-of-function RET that is causative of MTC. Interestingly,
immunohistochemical analysis shows that samples carrying S836S/3’UTR (GTCAC) haplotype
displayed stronger RET staining intensity than those without these variants (Fig 4). Although
the difference did not reach statistical significance, these observations may indicate an effect of
the polymorphic haplotype on RET expression.
Potential miRNAs recognition site are identified in 3' UTR regions, thus, it is reasonable to
speculate that the 3’UTR polymorphism could be involved in a ligation site for a given miRNA,
interfering the RET expression. Therefore, we used the TargetScan and miRDB softwares to
look for potential miRNA targets in the 3’UTR of RET gene. We can observe that the RET
3’UTR variants (rs3026758 and rs76759170) are situated near to several miRNA-binding sites,
but none of them is situated in the miRNA seed region. The miRNA-binding sites for the hsa-
miR-27a, hsa-miR-27b, hsa-miR-128a, hsa-miR-216a-3p and hsa-miR-3681-3p are situated
near to rs76759170, although this variant is not in the miRNA seed region. Similar results were
found to the hsa-miR-590-3p and the rs3026785. Additional studies are warranted to further
explore this issue.
Conclusion
Our results demonstrate linkage disequilibrium between RET S836S and 3’UTR genetic vari-
ants. The patients harboring S836S/3’UTR haplotype presents more aggressive disease as com-
pared to those harboring the other haplotypes. Furthermore, the RETmRNA sequence
carrying the S836S/3’UTR haplotype present higher structural and thermodynamic stability,
supporting the hypothesis of a functional involvement of the 3’UTR variant allele in the post-
transcriptional control of a RET transcripts
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